Search

Search Constraints

You searched for: Author/Creator Callanan, M.

Search Results

1. FIRST LINE TREATMENT BY THE RIBVD REGIMEN ELICITS HIGH CLINICAL AND MOLECULAR RESPONSE RATES AND PROLONGED SURVIVAL IN ELDERLY MCL PATIENTS; FINAL RESULTS OF a LYSA GROUP TRIAL. (June 2017)

3. P451: PRMT2: AN ANTI-INFLAMMATORY EPIGENETIC FACTOR INVOLVED IN ACUTE MYELOID LEUKEMIA AGGRESSIVENESS. (23rd June 2022)